Effect of benralizumab and mepolizumab on the AHR to QS
Both benralizumab and mepolizumab prevented the hyperresponsive myogenic tone induced by QS in passively sensitized bronchi.
Benralizumab administered at concentrations ≥10 μg/ml significantly reduced the AHR when compared with C+ bronchi (-499.43±9.98 mg/100mg bronchial tissue, P<0.01 vs. C+), conversely at least 30 μg/ml of mepolizumab were necessary to induce the same significant effect in hyperresponsive airways (-381.54±45.90 mg/100mg bronchial tissue, P<0.01 vs. C+) (Figure 6). Benralizumab at 10 μg/ml, but not mepolizumab, inhibited the contractile response to QS at a level significantly (P<0.05) lower than that detectable in C- tissue.